Soligenix Completes Promising Study on Dusquetide for Behcet’s Disease

Soligenix Inc ((SNGX)) announced an update on their ongoing clinical study.

Soligenix Inc. has recently completed a clinical study titled ‘Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behcet’s Disease.’ The study aimed to evaluate the efficacy of dusquetide in treating oral and genital ulcers caused by Behcet’s Disease, a condition characterized by painful flare-ups. The significance of this study lies in its potential to offer a new treatment option for patients suffering from this chronic condition.

The intervention tested in this study was dusquetide, a drug administered as a 1.5 mg/mL intravenous infusion. Participants received this treatment twice a week for four weeks, totaling eight treatments, with additional follow-up visits for four weeks. The purpose of dusquetide is to reduce the frequency and severity of ulcer flare-ups in Behcet’s Disease patients.

This Phase 2 interventional study followed a single-group assignment model, meaning all participants received the same treatment without a control group. The study was open-label, so both researchers and participants knew what treatment was being administered. The primary purpose of the study was to assess the treatment’s effectiveness.

The study began on November 18, 2024, and was completed with the last update submitted on July 31, 2025. These dates are crucial as they mark the timeline of the study’s progression and the availability of updated information for stakeholders.

The completion of this study could positively impact Soligenix’s stock performance by enhancing investor confidence in the company’s research capabilities and potential market expansion. As the pharmaceutical industry continuously seeks innovative treatments, successful outcomes from this study could position Soligenix favorably against competitors.

The study is now completed, with further details available on the ClinicalTrials portal.